• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Find Out What Makes the Flu Vaccine Market a Highly Challenging Sector With This New Report

Posted on: Wednesday, 29 August 2007, 15:12 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c66946) has announced the addition of Datamonitor's latest title "Pipeline And Commercial Insight: Influenza Vaccines - Pandemic Threat Revitalizes The Sector" to their offering.

The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only large players are able to cope with the need for annual updates and the costly manufacturing process. However, driven by the increasing pandemic threat, the market is growing fast and is predicted to more than double in size by 2016.

Scope of this title:

Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and of key companies in the sector Thorough assessment of underlying commercial and clinical influencers shaping the influenza vaccine market Patient-based forecasts for the influenza vaccine market taking into account recommended vaccination groups and coverage rates in the 7 major markets In-depth comparative analysis of both seasonal and pandemic influenza vaccine pipeline candidates and discussion of their future potential

Highlights of this title:

The demand for influenza vaccines is highly variable and the time window for the vaccination is limited to just a few months per year. This, in combination with the need for annual updates and the long planning cycles required due to the lengthy egg-based manufacturing process, makes the flu vaccine market a highly challenging sector. The pandemic threat has acted as an important driver for the seasonal vaccine market. Rising public awareness of influenza has increased the demand for seasonal vaccination. Government funding provided for pandemic research is also benefiting seasonal vaccine development through technology transfer. With Novartis cell-based Optaflu currently awaiting EU approval and ProteinSciences baculovirus-based FluBlØk in phase III, new production techniques available are shaping up to change market dynamics. Further advances include adjuvanted vaccines, and, in earlier development stages, DNA- and universal vaccine candidates.

Reasons to order your copy:

Review the clinical and commercial factors driving new product decisions in influenza vaccines and the strategies of key players in the market Gain insight through a patient-based forecast and a thorough analysis of the seasonal and pandemic influenza vaccine pipeline Understand where concerns, unmet needs and future opportunities lie by learning about the views of key influenza vaccine opinion leaders

Key Topics Covered Include:

- About Our Healthcare

- About the Infectious Diseases Pharmaceutical Analysis team

- Executive summary

- Epidemiology

- Transmission and symptoms

- Preparing for disaster - national and international pandemic planning

- Market definition and overview

- Current players and their strategies

- Patient-based forecast analysis

- R&D approach

- Pipeline analysis seasonal influenza

For more information visit http://www.researchandmarkets.com/reports/c66946

Source: Datamonitor

Source: Business Wire

More News in this Category